The latest announcement is out from Xlife Sciences Ltd. ( (CH:XLS) ).
Xlife Sciences Ltd. announced that its portfolio company, VERAXA Biotech AG, will merge with NASDAQ-listed Voyager Acquisition Corp., valuing VERAXA at USD 1.64 billion. This strategic merger will enable VERAXA to go public on the NASDAQ, enhancing its visibility in the global biotech market and providing access to institutional investors. The merger is expected to significantly accelerate VERAXA’s ability to develop next-generation cancer therapies, leveraging its innovative BiTAC platform to address challenges in cancer treatment with higher efficacy and safety.
More about Xlife Sciences Ltd.
Xlife Sciences is a Swiss company that acts as an incubator and accelerator, focusing on the development and commercialization of promising research projects in the life sciences sector. The company aims to bridge the gap from research and development to healthcare markets by advancing projects in technology platforms, biotechnology/therapies, medical technology, and artificial intelligence/digital health.
YTD Price Performance: -21.26%
Average Trading Volume: 4,811
Current Market Cap: CHF114.8M
Learn more about XLS stock on TipRanks’ Stock Analysis page.